Vimarsana
Biggest News Aggregation in the World

Page 20 - Prospectus Rules News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Prospectus Rules. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Prospectus Rules Today - Breaking & Trending Today

Rights and Issues Investment Trust PLC: Final -3- - Vimarsana News

Rights and Issues Investment Trust PLC: Final -3-

DJ Rights and Issues Investment Trust PLC: Final Results for the year to 31st December 2021 Rights and Issues Investment Trust PLC (RIII) Rights and Issues Investment Trust PLC: Final Results for

Aelis Farma, a biopharmaceutical company developing a new generation of drugs for brain diseases, announces the success of its initial public offering and raises approximately €25 million on Euronext Paris - Vimarsana News

Aelis Farma, a biopharmaceutical company developing a new generation of drugs for brain diseases, announces the success of its initial public offering and raises approximately €25 million on Euronext Paris

16.02.2022 - Regulatory News: Aelis Farma (Paris: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases (the 'Company'), announces today the successful completion of its initial public offering on ...

Aelis Farma, a biopharmaceutical company developing a new generation of drugs for brain diseases, announces the success of its initial public offering and raises approximately €25 million on Euronext Paris - Vimarsana News

Aelis Farma, a biopharmaceutical company developing a new generation of drugs for brain diseases, announces the success of its initial public offering and raises approximately €25 million on Euronext Paris

Capital increase of approximately €25 million, i.e. 100% of the initial objective, despite high market volatility Size of the transaction which may be increased to approximately €25.55 million

Aelis Farma, a Biopharmaceutical Company Developing a New Generation of Drugs for Brain Diseases, Launches Its Initial Public Offering on the Regulated Market of Euronext Paris - Vimarsana News

Aelis Farma, a Biopharmaceutical Company Developing a New Generation of Drugs for Brain Diseases, Launches Its Initial Public Offering on the Regulated Market of Euronext Paris

02.02.2022 - Regulatory News: Not to be distributed, directly or indirectly, in the United States of America, Canada, Australia, Japan or South Africa. Aelis Farma, a clinical-stage biopharmaceutical company specializing in the development of treatments for ...

Aelis Farma, a Biopharmaceutical Company Developing a New Generation of Drugs for Brain Diseases, Launches Its Initial Public Offering on the Regulated Market of Euronext Paris - Vimarsana News

Aelis Farma, a Biopharmaceutical Company Developing a New Generation of Drugs for Brain Diseases, Launches Its Initial Public Offering on the Regulated Market of Euronext Paris

Capital increase of €25 million, which may be increased to a maximum of approximately €33 million in the event the Extension Clause and the Over-Allotment Option are fully exercised Irrevocable